(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
‘This year nearly broke me as a scientist’ – US researchers reflect on how 2025’s science cuts have changed their lives - 2Well known SUVs With Low Energy Utilization In 2024
- 3Figure out How to Explore the Infotainment Framework in the Slam 1500.
- 4Embrace the Outside: Exercises and Entertainment
- 5A Sweet Choice: Pick Your #1 Cake!
- She just became the first wheelchair user to travel to space
- All that You Really want to Be aware of Dental Inserts Facilities
- NASA wants to build a base on the Moon by the 2030s – how and why it plans to build up to a long-term lunar presence
- Poland open to German troops to help secure Ukraine ceasefire
- Vote In favor of Your Favored Kind Of Vegetable
- German state railway loss widens, passengers warned of trouble ahead
- The Solution to Individual budget: Dominating Cash The board
- Pedal Power: Divulging Well known Bike Brands for Each Cyclist
- Activists Took BMW and Mercedes to Court Over Gas Cars. It Didn’t Stick
